Epidemiology and Resistance in Aspergillus and other Moulds
|
|
- Alfred Newman
- 5 years ago
- Views:
Transcription
1 Epidemiology and Resistance in Aspergillus and other Moulds Nathan Wiederhold, PharmD Associate Professor Director, Fungus Testing Laboratory Invasive Mould Infections Often opportunistic Associated with significant morbidity and mortality in immunocompromised hosts Hematologic malignancies HSCT recipients (allogeneic & autologous) SOT recipients (lung, heart, liver, kidney, etc) Limited treatment options for some Order Mucorales Fusarium species / Lomentospora species Knowledge of fungal taxonomy increasing Diagnostic strategies some what lacking IFIs Organ Transplant Recipients TRANSNET organ transplant recipient database (00 006) Proven or probable IFIs from 5 U.S. centers Invasive Fungal Infections Surveillance Cohort (0 IFI in 063 pts) Incidence Cohort (79 IFI in 633 pts) Invasive candidiasis 5.9% 56% Invasive aspergillosis.%.% Cryptococcosis.0% 6.7% Other moulds 6.5%.% Unspecified moulds.0%.% Endemic fungi 5.3%.% Mucormycosis.3%.% -month cumulative incidence for any IFI 3.% (0.7% for IA; ~0.% other moulds) Pappas et al. Clin Infect Dis 00;50:0-. IMI Lung Transplant Recipients 73 lung transplant recipients at of 5 TRANSNET SOT centers 3 (.%) developed invasive mould infections (00 006) IMIs occurred median months post-transplant Majority late onset (>90 days) 6 months for mucormycosis Doligalski et al. Am J Transpl 0;: Species Percent Aspergillus 7.7% Other moulds 6.% No culture.9% 3.5% Mucorales.% Other moulds = Acremonium, Alternaria, Chrysosporium, Cladosporium, Exophiala, Microascus, Ochroconis, Paecilomyces, Paraphaeosphaeria, Penicillium, Phaeoacremonium, Phialemonium, Rhinocladiella, Scopulariopsis, Trichoderma (several phaeoid species)
2 IFIs HSCT Recipients TRANSNET organ transplant recipient database (00 006) Proven or probable IFIs from U.S. centers Invasive Fungal Infections Surveillance Cohort (93 IFI in 76 pts) Incidence Cohort (7 IFI in 639 pts) Invasive aspergillosis 3% % Invasive candidiasis % 30% Mucormycosis.0% 9.0% Other moulds 7.0% 5.0% Unspecified moulds 6.0% 6.0% Fusariosis 3.0% 3.0% Endemic fungi 0.6% 0.% -month cumulative incidence for any IFI 3.% (0.9% - 3.% range by site) Kontoyiannis et al. Clin Infect Dis 00;50: IFI HSCT PATH Alliance 3 medical centers U.S. & Canada, July 00 to September proven/probable IFI in 3 HSCT patients Invasive Fungal Infection Proven/Probable Week Mortality Invasive aspergillosis 59.% 35.9% Invasive candidiasis.%.9% Mucormycosis 7.% 6.3% Other moulds 6.% 0% Other Moulds Mucormycosis Invasive Aspergillosis Invasive Candidiasis Neofytos et al. Clin Infect Dis 009; : Proportion Clinical Outcome Complete/Partial Stable Worse Unknown TRANSNET Phaeohyphomycosis Included in the other moulds category 56 of 9 (.6%) IFI in TRANSNET cohort Similar divided between HSCT & SOT recipients Pulmonary infections in HSCT recipients (57.7% vs. 6.7%) Overall 90 day mortality higher HSCT (% vs. 0%) Cutaneous infections in SOT recipients (53.3% vs. 3.%) Species (n = 56 isolates total) No. Isolates (%) No. Deaths (%) Alternaria (3.%) 6 (33.3%) Exophiala 6 (0.7%) 0 Cladophialophora 5 (.9%) (0%) Scopulariopsis 5 (.9%) (0%) Curvularia (7.%) (5%) Phialemonium (7.%) (5%) Exserohilum 3 (5.%) (33.3%) McCarty et al. Med Mycol 05;53:0-6. Aspergillosis Acute invasive aspergillosis Estimated ~00,000 cases/year Leading cause of invasive mould infections SOT recipients (TRANSNET) Lung transplant recipients (TRANSNET) HSCT recipients (TRANSNET & PATH Alliance) Leading cause IFI in HSCT recipients Chronic pulmonary aspergillosis Estimated >3 million people infected worldwide Common with underlying lung disease Tuberculosis, sarcoidosis Denning et al. Bull World Health Organ 0;9:6-7. Denning et al. Eur Respir J 03;:6-66. Denning et al. Med Mycol 03;5:
3 Percent Resistant Percent Resistant 5/5/07 Ubiquitous mould Microbiology >00 spp. Aspergillus Common causes of infections in humans A. flavus - A. terreus - A. niger - A. fumigatus Conidia inhaled and may evade upper respiratory defenses - Germinate into angioinvasive hyphae local tissue damage hemorrhage, infarction coagulative necrosis Antifungal Activity vs. A. fumigatus Parameter Itraconazole Voriconazole Posaconazole MIC Range <0.03 >6 μg/ml >6 μg/ml <0.03 >6 μg/ml MIC μg/ml 0.5 μg/ml 0.5 μg/ml MIC90 μg/ml μg/ml 0.5 μg/ml GM MIC μg/ml 0.56 μg/ml 0.9 μg/ml % Itraconazole (n = 6) A. fumigatus Overall Resistance 3.6%.06% Voriconazole (n = 76) Posaconazole (n = 3) A. fumigatus Resistance Matched Isolates (N = 396) 5.% 3.76%.00% Itraconazole Voriconazole Posaconazole Wiederhold et al. Advances Against Aspergillosis 0. Azole Resistance in Aspergillus Modification of Target Enzyme Point mutations in CYP5A (gene encoding for demethylase azole target) observed in A. fumigatus clinical and laboratory isolates with azole resistance Position of point mutation determines azole resistance Some pan-azole, other affect voriconazole & isavuconazole, other affect posaconazole Historically observed with chronic azole exposure Patients with chronic pulmonary aspergillosis (Manchester, UK) Mann et al. AntimicrobAgents Chemother 003;7: Mellado et al. AntimicrobAgents Chemother 00;:77. Howard et al. Emerg Infect Dis 009;5: Seyedmousavi et al. Drug Resist Updat 0;7: Environmental Exposure to Azoles Azole-resistant IA identified in patients without prior azole exposure in parts of Europe Indoor environment in hospitals & direct proximity to medical centers Fields where azole fungicides used Used in agriculture to combat crop failure & other products to prevent rotting Mechanisms of azole resistance in environmental isolates & azole-naïve patients TR 3 /L9H TR 6 /YF/T9A TR 53 Snelders et al. Appl Environ Microbiol 009;75: Chowdhary et al. PLoS One 0;7:e57. van der Linder et al. Clin Infect Dis 03;57: Chowdhary et al. J Antimicrob Chemother 0;69: Chowdhary et al. J Antimicrob Chemother 0;69:
4 Worldwide Issue Continent/Country Percent Resistance Isolate Source Europe (G5, M, GS, G3, TR 3/L9H, TR 6/YF/T9A, TR 53) Belgium 5.7% Clinical France % Clinical Germany. % Clinical & Environmental Netherlands. 0% Clinical & Environmental Poland.3% Clinical Spain.% Clinical Turkey 0.% Clinical United Kingdom 6.6 % Clinical North & South America (G5, M, GS, G3, TR 3/L9H, TR 6/YF/T9A, TR 53) United States 0.6.% Clinical Colombia (TR 53) 3.3% Environmental Africa (TR 3/L9H, TR 6/YF/T9A) Tanzania 3.9% Environmental Asia & Australia (G5, M, GS, TR 3/L9H, TR 6/YF/T9A) Australia.6% Clinical China, India, Iran, Japan, Kuwait, Pakistan.9.% Clinical & Environmental Rivero-Menendez J Fungi 06;; doi:0.3390/jof0300. Azole Resistance - FTL Results 0 of 6 isolates confirmed to be A. fumigatus & with elevated azole MICs had CYP5A mutations TR 3 /L9H or TR 6 /YF/T9A mutations each found in two isolates First TR 6 /YF/T9A mutation (00) predates first one found in Europe (the Netherlands, 009) Patients with proven disease & without travel history 6 azole resistant isolates without CYP5A mutation Wiederhold et al. J Clin Microbiol 06;:6-7. Other Mechanisms of Resistance Mechanism Overexpression CYP5B Efflux pumps Cholesterol import GOF mutation in HapE Comments Cyp5p encoded by cyp5a & cyp5b CYP5A important in regulating -α-demethylase activity CYP5B associated with growth rate & cell maintenance Role CYP5B in azole resistance unclear ~50 ABC family transporters & ~300 MFS genes predicted in A. fumigatus Overexpression of CDRB, AfuMDR, AfuMDR, AfuMDR3, AfuMDR (biofilm resistance) & ATRF associated with azole resistance in vitro Little known about efflux pumps and in vivo resistance Import of exogenous cholesterol as substitute for ergosterol after azole treatment SrbA (sterol-regulatory element binding protein) plays role in resistance HapE is a CCAAT-binding transcription factor complex subunit PL mutation in HapE-complex & binding to CCAAT-box in promoter region can induce CYP5A expression Aspergillus Antifungal Resistance Two phenomena associated with resistance to antifungal agents in IFIs caused by Aspergillus. Secondary azole-resistance in A. fumigatus isolates. Increase in number of infections due to non-a. fumigatus isolates Emerging species with primary resistance to azoles Mellado et al. J Clin Microbiol 00;39:3-3. Bueid et al. J Antimicrob Chemother 03;6:5-5. Chamilos & Kontoyiannis Drug Resist Updat 005;:3-35. Rajendran et al. Antimicrob Agents Chemother 0;55: Ferreira et al Med Mycol 005;3(suppl ):S Slaven et al. Fungal Genet Biol 00;36: Fraczek et al. J Antimicrob Chemther 03;6:6-96. Willger et al. PLoS Pathog 00;:e Camps et al. PLoS One 0;7:E5003. Goncalves et al. Mycoses 06;59:9-9.
5 Cryptic Aspergillus Species Leading causes of IA: A. fumigatus (5% 60%) A. flavus (6% 0%) A. terreus (% 0%) A. niger (% - 9%) Molecular tools led to description of new species Cryptic or sibling species difficult to differentiate by classic means (phenotype/morphology alone) TRANSNET (U.S.: ) - % cryptic species among Aspergillus isolates A. lentulus (.%), A. udagawae (.%), A. tubingensis (.%), A. calidoustus (.%) FILPOP (Spain: Oct. 00 & May 0).5% cryptic species among 33 Aspergillus isolates A. lentulus (.%), A. alliaceus (.%), A. tubingensis (7.9%), A. calidoustus (.%) Rivero-Menendez J Fungi 06;; doi:0.3390/jof0300. Balajee et al. J Clin Microbiol 009;7:33-3. Kontoyiannis et al. Clin Infect Dis 00;50: Pappas et al. Clin Infect Dis 00;50:0-. Alastruey-Izquierdo et al. Antimicrob Agents Chemother 03;57: Aspergillus Section Fumigati (aka A. fumigatus Species Complex) 5 phylogenetically distinct species Difficult to distinguish phenotypically Unstable morphology Identification requires molecular/proteinomic means DNA sequences analysis (β-tubulin, calmodulin) MALDI-TOF Balajee et al. Stud Mycol 007;59:39-6. Sugui et al. J Clin Microbiol 0;5: Samson et al. Stud Mycol 0;7:-73. Aspergillus Section Fumigati (aka A. fumigatus Species Complex) At least 5 reported to have caused disease in humans Aspergillus species A. felis, A. fumigatiaffinis, A. fumigatus, A. fumisynnematus, A. lentulus, A. novofumigatus, A. parafelis, A. pseudofelis, A. pseudoviridinutans, A. viridinutans Previously Neosartorya species A. fischeri (N. fischeri), A. hiratsukae (N. hiratsukae), A. thermomutatus (N. pseudofischeri), and A. udagawae (N. udagawae) Several with reduced azole susceptibility Species AMB ITR VOR A. fumigatus A. lentulus A. viridinutans 0.5 A. felis A. parafelis >6 A. pseudofelis >6 A. pseudoviridinutans >6 Infections include: IPA, osteomyelitis, peritonitis, cerebral aspergillosis, etc. Sugui et al. J Clin Microbiol 0;5: Balajee et al. J Clin Microbiol 005;3: Matsumoto et al. Pediatr Nephrol 00;7:3-5. Jarv et al. 00; J Clin Microbiol 00;:95-9. Zbinden et al. Transpl Infect Dis 0;:E Ghebremedhin et al. J Med Microbiol 009:5:67-6. Other Aspergillus Sections/Species Flavi Section Species Antifungal Susceptibility Nidulantes Nigri Terrei A. flavus A. alliaceus A. nidulans A. delacroxii A. quadrilineatus A. niger A. tubingensis A. terrei A. alabamensis A. citrinoterreus Reduced susceptibility to AMB and echinocandins Variable AMB susceptibility Azole susceptible Variable azole susceptibility Reduced AMB susceptibility Usti A. calidoustus Reduced AMB and azole susceptibility Versicolores A. sydowii A. versicolor Variable AMB susceptibility & reduced azole susceptibility NOT A COMPREHENSIVE LIST! 5
6 Mucormycosis Study Prevalence IMI Rank TRANSNET - SOT.3% TRANSNET - Lung SOT.% 3 TRANSNET - HSCT.0% Johns Hopkins (HSCT & SOT).3 -.9% & 3 UT MD Anderson (Hematol. malignancies - autopsy).5% France. cases/million population/year Spain 0. cases/million population/year California.7 cases/million population/year Pappas et al. Clin Infect Dis 00;50:0-. Doligalski et al. Am J Transpl 0;: Kontoyiannis et al. Clin Infect Dis 00;50: Neofytos et al. Transpl Infect Dis 03;5:33-. Lewis et al. Mycoses 03;56: Bitar et al. Emerg Infect Dis 009:5: Rees et al. Clin Infect Dis 99;7:3-7. Pagano et al. Haematologica 00;6:6.70. Causative Agents Mucormycosis Genera Apophysomyces Cunninghamella Lichtheimia (formerly Absidia) Mucor Rhizomucor Rhizopus Saksenaea Representative Species (not comprehensive) A. elegans, A. trapeziformis, A. variabilis C. bertholletiae, C. echinulata L. corymbifera, L. ornata, L. ramosa M. circinelloides (f. circinelloides & f. janssenii), M. irregularis R. pusillus R. arrhizus, R. microsporus, R. schipperae S. erythrospora, S. oblongispora, S. vasiformis Rhizopus arrhizus (oryzae) Major cause of mucormycosis in United States 55% mucormycosisinfections in PATH Alliance HSCT patients Very aggressive; high morbidity & mortality (immunocompromised) Difficult to treat with limited options (increasing) R. arrhizus var. arrhizus & R. arrhizus var. delemar Is Rhizopus delemar a Separate Species? (R. arrhizus var. delemar OR R. delemar) Phylogenetically distinct ITS & multilocus analysis In agreement with other studies R. arrhizus able to produce lactic acid R. delemar lack ldha gene; cannot produce lactic acid fumaric and malic acid Abe et al. Mycologia 007;99:7-7. Dolatabadi et al. Mycoses 0;57(Suppl. 3):0-7. Species Clinical Significance? Isolate Number VT-6 MIC (mg/l) R. arrhizus var. arrhizus RA 0.5 R. arrhizus var. arrhizus RA R. arrhizus var. arrhizus RA5 0.5 R. arrhizus var. arrhizus RA 0.5 R. arrhizus var. arrhizus RA9 0.5 R. arrhizus var. arrhizus RA0 R. arrhizus var. arrhizus RA* R. arrhizus var. delemar RA3 >3 R. arrhizus var. delemar RA >3 R. arrhizus var. delemar RA6 R. arrhizus var. delemar RA7 >3 R. arrhizus var. delemar RA 6 Antifungal R. arrhizus R. delemar Amphotericin B Itraconazole Posaconazole Fungus Testing Laboratory Internal Results (0 months data - 3 R. arrhizus var. arrhizus & 9 var. delemar) Gebremariam et al. Antimicrob Agents Chemother 05;59:
7 MIC (mg/ml) MIC (mg/ml) MIC (mg/ml) MIC (mg/ml) 5/5/07 Scedosporiosis Invasive infections primarily in immunocompromised hosts Breakthrough infections in persistently neutropenic and/or lymphopenic hosts Enters through sinopulmonary route & causes pulmonary infection; difficult to distinguish from invasive aspergilosis Common colonizers of cystic fibrosis patients Infections can occur in survivors of neardrowning events Pulmonary infections with dissemination to the CNS Species apiospermum aurantiacum boydii dehoogii minutispora desertorum Lomentospora prolificans Species Comment Previously considered to be anamorph of Pseudallescheria boydii Maybe less susceptible to posaconazole Reduced AMB & azole susceptibility Previously Pseudallescheria boydii Rare Reduced voriconazole susceptibility Previously Pseudallescheria minutispora Previously Pseudallescheria desertorum Previously prolificans (now separate genus) Highly drug resistant species cannot be reliable differentiated by morphology Requires DNA sequence analysis or MALDI-TOF MALDI-TOF Dendrogram (FTL Internal Data) Gilgado et al. J Clin Microbiol 00:6: Lackner et al. Fungal Diversity 0;67:-0. Antifungal Activity S. apiospermum F903 Amphotericin Caspofungin Posaconazole Voriconazole S. boydii F903 Amphotericin Caspofungin Posaconazole Voriconazole S. aurantiacum & S. dehoogii F903 Amphotericin Caspofungin Posaconazole Voriconazole L. prolificans F903 Amphotericin Caspofungin Posaconazole Voriconazole Fusariosis Significant cause of morbidity and mortality in immunocompromised hosts Usually invasive and disseminated (bloodstream) Neutropenic patients with acute leukemia Severe T-cell deficiency (corticosteroids for GVHD) Poor prognosis (although improving) Species F903 Amphotericin Caspofungin Posaconazole Voriconazole S. apiospermum (3) S. boydii (5) S. aurantiacum & S. dehoogii (6 & ) > L. prolificans (7) 0.6 >6 > >6 >6 Fothergill et al. ECCMID 06. Nucci et al. Clin Infect Dis 00;3:37-. Nucci et al. Clin MicrobiolInfect 0;0: Period : Period :
8 Fusarium Species Human infections can be caused by species complexes Etiologic agents Fusarium solani spp. Complex (FSSC) for majority of Fusarium oxysporum spp. Complex (FOSC) infections Fusarium fujikuroi spp. Complex (FFSC) Fusarium chlamydosporum spp. Complex (FCSC) Fusarium dimerum spp. Complex (FDSC) Fusarium incarnatum-equiseti spp. Complex (FIESC) Fusarium sambucinum spp. Complex (FSAMSC) Fusarium tricinctum spp. Complex (FTSC) O Donnell et al. J Clin Microbiol 007;5:35-. Fusarium solani Species Complex Composed of numerous haplotypes, many of which are now considered separate species Those that cause infections in humans F. petroliphilum (haplotype ) F. keratoplasticum (haplotype ) F. falciforme (haplotype 3+) F. solani (haplotype 5) Other species/haplotypes cause disease in animals & plants Major plant pathogen Identification to species level requires MLST EFα, RPB Clinical relevance of different species in FSSC unknown (most clinical laboratories do not identify to this level) O Donnell et al. Fungal Genet Biol 03;5:0-3. Summary Invasive mould infections significant causes of morbidity & mortality in immunocompromised patients Aspergillus, Mucorales,, & Fusarium species Other moulds can also cause disease in these populations Although new antifungals are available & under development, continued work needed due to resistance (intrinsic & acquired) Epidemiology & clinical understanding of causes of IMI infections changing due to use of molecular/ proteinomic assays for species identification
Insights into Antifungal Resistance & Newer (Other) Moulds
Insights into Antifungal Resistance & Newer (Other) Moulds Nathan P. Wiederhold, PharmD Fungus Testing Laboratory (FTL) Department of Pathology & Laboratory Medicine South Texas Reference Laboratories
More informationResistance epidemiology
ECMM/EFISG symposium: Multidrug resistance in fungi? A formidable foe Resistance epidemiology Ana Alastruey Izquierdo Mycology Reference Lab Spain Instituto de Salud Carlos III Disclousure I have received
More informationAUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA : PART 2 THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM.
AUSTRALIAN ANTIFUNGAL SUSCEPTIBILITY DATA 00-0: PART THE MOULDS ASPERGILLUS, SCEDOSPORIUM AND FUSARIUM. AUSTRALIAN Sarah Kidd, Rose Handke and ANTIFUNGAL David Ellis SUSCEPTIBILITY DATA 00-00 David SA
More informationAntifungal Pharmacotherapy
Interpreting Antifungal Susceptibility Testing: Science or Smoke and Mirrors A. W. F O T H E R G I L L, M A, M B A U N I V E R S I T Y O F T E X A S H E A L T H S C I E N C E C E N T E R S A N A N T O
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationAntifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study.
1 Antifungal Susceptibility of Aspergillus Isolates from the Respiratory Tract of Patients in Canadian Hospitals: Results of the CANWARD 2016 Study. J. FULLER 1,3, A. BULL 2, S. SHOKOPLES 2, T.C. DINGLE
More informationTreatment of rare and emerging fungal infections. EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen
Treatment of rare and emerging fungal infections EFISG Educational Workshop 15 th ECCMID April 2, 2005, Copenhagen Helen Sambatakou Lecturer in Medicine and Infectious Diseases, University of Athens, Greece
More informationAna Espinel-Ingroff 1, Elizabeth Johnson 2, Hans Hockey 3 and Peter Troke 4 *
Journal of Antimicrobial Chemotherapy (2008) 61, 616 620 doi:10.1093/jac/dkm518 Advance Access publication 25 January 2008 Activities of voriconazole, itraconazole and amphotericin B in vitro against 590
More informationIn vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic?
4 th Congress on Trends in Medical Mycology (TIMM) In vitro cross-resistance between azoles in Aspergillus fumigatus: a reason for concern in the clinic? Emilia Mellado Mycolgy Reference Laboratory Centro
More informationEpidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Review article Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus Sarah Santos Goncßalves, 1 Ana Carolina
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationIn vivo response in a mixed infection model of azole susceptible and resistant Aspergillus spp. strains Laura Alcazar-Fuoli, CNM, ISCIII
In vivo response in a mixed infection model of azole susceptible and resistant Aspergillus spp. strains Laura Alcazar-Fuoli, CNM, ISCIII Pre-Advances Against Aspergillosis Workshop: Aspergillus Speciation
More informationEpidemiology of Invasive Mold Infections in Lung Transplant Recipients
American Journal of Transplantation 2014; 14: 1328 1333 Wiley Periodicals Inc. C Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons doi: 10.1111/ajt.12691
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationAntifungal resistance in Aspergillus fumigatus
Antifungal resistance in Aspergillus fumigatus Dr Lily Novak Frazer and Dr Caroline Moore University of Manchester at the Manchester Academic Health & Science Centre and the Mycology Reference Centre,
More information23rd ECCMID, Apr Berlin
23rd ECCMID, 27-30 Apr 2013 - Berlin www.flickr.com Prof. Sevtap Arikan-Akdagli, MD Hacettepe University Medical School Department of Medical Microbiology Ankara Turkey Background information & moulds
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationAntifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences
5th MMTN Conference 5-6 November 2016 Bangkok, Thailand 10:20-10:45, 6 Nov, 2016 Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences Yee-Chun Chen, M.D., PhD. Department of Medicine,
More informationNew triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
For reprint orders, please contact reprints@expert-reviews.com New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance Expert Rev. Anti Infect. Ther. 7(8), 981 998
More informationGeorg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany.
www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany gmaschmeyer@klinikumevb.de www.dghoinfektionen.de 519 A. fumigatus isolates: Itraconazole
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY Species identification of Aspergillus, Fusarium and Mucorales with direct surface analysis by matrix-assisted laser desorption ionization time-of-flight mass spectrometry E. De
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationWhat are the Clinical Implications of Antifungal Resistance: Aspergillus/Moulds & Clinical Trials
What are the Clinical Implications of Antifungal Resistance: Aspergillus/Moulds & Clinical Trials Thomas F. Patterson, MD, FACP, FIDSA Professor of Medicine Chief, Division of Infectious Diseases Director,
More informationZygomycosesn existent plus.! Kwon-Chung et al. CID 2012
Zygomycosesn existent plus.! < Kwon-Chung et al. CID 2012 < Epidemiologyand treatmentof mucormycosis Olivier Lortholary, M.D.; Ph.D. Université Paris Descartes, Service de Maladies Infectieuses et Tropicales
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationThermotolerant filamentous fungi in belgian hospitals: 15 years of survey
BVMDM-SBMHA, November 14, 2013- Ophain Françoise SYMOENS Thermotolerant filamentous fungi in belgian hospitals: 15 years of survey Fungi in hospitals (species and amount) Different settings/context Analyse
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationInvasive Fungal Infections in Solid Organ Transplant Recipients
Outlines Epidemiology Candidiasis Aspergillosis Invasive Fungal Infections in Solid Organ Transplant Recipients Hsin-Yun Sun, M.D. Division of Infectious Diseases Department of Internal Medicine National
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationPhaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET)
Medical Mycology Advance Access published April 23, 2015 Medical Mycology, 2015, 00, 1 7 doi: 10.1093/mmy/myv018 Advance Access Publication Date: 0 2015 Original Article Original Article Phaeohyphomycosis
More informationClinical relevance of resistance in Aspergillus. David W. Denning University Hospital of South Manchester [Wythenshawe Hospital]
Clinical relevance of resistance in Aspergillus David W. Denning University Hospital of South Manchester [Wythenshawe Hospital] The University of Manchester Steps to establishing clinical validity of resistance/susceptibility
More informationDimitrios P. Kontoyiannis, MD, ScD. Frances King Black Endowed Professor
Dimitrios P. Kontoyiannis, MD, ScD Frances King Black Endowed Professor Disclosures Research support from Merck, Pfizer and Astellas and has served as speaker for Gilead/Merck, Mylan, Inc and as consultant
More informationAbout the Editor Gerri S. Hall, Ph.D.
About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year
More informationFirst Detection of TR34/L98H and TR46/Y121F/T289A Cyp51 Mutations in. Aspergillus fumigatus isolates in the United States
JCM Accepted Manuscript Posted Online 21 October 2015 J. Clin. Microbiol. doi:10.1128/jcm.02478-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12 13
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationAntifungal resistance mechanisms in pathogenic fungi
Antifungal resistance mechanisms in pathogenic fungi Shivaprakash M Rudramurthy Additional Professor, Mycology Division Center of Advanced Research in Medical Mycology, National Culture Collection of Pathogenic
More informationmycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Dimitrios P. Kontoyiannis, 1 Nkechi Azie, 2 Billy
More informationMBT Filamentous Fungi Library. Innovation with Integrity. MALDI Biotyper MALDI-TOF
MBT Filamentous Fungi Library MALDI Biotyper Innovation with Integrity MALDI-TOF MALDI Biotyper Tackle the filamentous fungi challenge The MALDI Biotyper has revolutionized the identification of microorganisms
More informationFilamentous fungi MALDI-TOF identification
Filamentous fungi MALDI-TOF identification Stéphane Ranque Parasitologie & Mycologie AP-HM Timone Marseille, France stephane.ranque@ap-hm.fr Aspergillus flavus Aspergillus ochraceus Conidia 3 to 6 µ Conidia
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationFDA BRIEFING DOCUMENT ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEETING JANUARY 22, APPLICANT: Astellas Pharma US, Inc.
FDA BRIEFING DOCUMENT ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEETING JANUARY 22, 2015 NDA 207-501: Cresemba (Isavuconazonium) for Injection NDA 207-500: Cresemba (Isavuconazonium) Capsules APPLICANT:
More informationVoriconazole. Voriconazole VRCZ ITCZ
7 7 8 7 8 fluconazole itraconazole in vitro in vivo Candida spp. C. glabrata C. krusei Cryptococcus neoformans in vitro Aspergillus spp. in vitro in vivo Aspergillus fumigatus Candida albicans C. krusei
More informationTailored Antifungal Modification in Breakthrough Mold Infections. Russell E. Lewis University of Bologna
Tailored Antifungal Modification in Breakthrough Mold Infections Russell E. Lewis University of Bologna 45 year-old patient with AML and documented pulmonary aspergillosis during remissioninduction chemotherapy
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationBroad spectrum triazoles: which drug and when?
Broad spectrum triazoles: which drug and when? Martin Hoenigl, PD, MD, FECMM Section of Infectious Diseases and Tropical Medicine, Department of Medicine, Medical University Graz, Austria AND Division
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationNEWS IN TERAPIA ANTIFUNGINA
Modena 19 maggio 2017 NEWS IN TERAPIA ANTIFUNGINA Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna About 1.2 billion people worldwide are estimated to suffer from a
More informationEpidemiology and ecology of fungal diseases
Epidemiology and ecology of fungal diseases Healthcare Focus on: - individual - diagnosis - treatment Public Health Focus on: - population - prevention The nature of fungi Kingdom Fungi (lat. fungus, -i)
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationManagement of fungal infection
Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general
More informationAspergillus species. The clinical spectrum of pulmonary aspergillosis
Pentalfa 3 maart 2016 The clinical spectrum of pulmonary aspergillosis Pascal Van Bleyenbergh, Pneumologie UZ Leuven Aspergillus species First described in 1729 * >250 species * ubiquitous Inhalation of
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationAntifungal Susceptibility Testing
Infect Dis Clin N Am 20 (2006) 699 709 Antifungal Susceptibility Testing Annette W. Fothergill, MA, MBA, MT(ASCP), CLS(NCA) a, Michael G. Rinaldi, PhD a,b, Deanna A. Sutton, PhD, MT, SM(ASCP), SM, RM(NRM)
More informationREVIEW. Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2
REVIEW Changing epidemiology of systemic fungal infections M. Richardson 1 and C. Lass-Flörl 2 1 Department of Bacteriology &Immunology, University of Helsinki, and Helsinki University Central Hospital
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance â registry David L. Horn, 1 Alison
More informationMycology. BioV 400. Subcutaneous Mycoses. Ecological associations. Geographic distribution World-wide
BioV 400 Mycology Handout 8 Subcutaneous Mycoses Lymphocutaneous sporotrichosis Chromoblastomycosis Phaeohyphomycosis Zygomycosis Mycetoma Lymphocutaneous sporotrichosis Sporothrix schenckii Chronic infection
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationASPERGILLOSIS IN THE NON-NEUTROPENIC HOST
ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationClinical Considerations in the Management of Systemic Fungal Infections. Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California
Clinical Considerations in the Management of Systemic Fungal Infections Conducted during the 41 st ASHP Midyear Clinical Meeting Anaheim, California CONTINUING EDUCATION ACCREDITATION The American Society
More informationEmerging Fungal Diseases
INVITED ARTICLE EMERGING INFECTIONS Larry J. Strausbaugh, Section Editor Emerging Fungal Diseases Marcio Nucci 1 and Kieren A. Marr 2,3 1 University Hospital, Universidade Federal do Rio de Janeiro, Rio
More informationEMA Pediatric Web Synopsis Protocol A November 2011 Final PFIZER INC.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationAspergillosis in Pediatric Patients
Aspergillosis in Pediatric Patients Emmanuel Roilides, MD, PhD, FIDSA, FAAM 3rd Department of Pediatrics Aristotle University School of Medicine Thessaloniki, Greece 1 Transparency disclosures Independent
More informationNationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationUpdate from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance 13
Fungal Infections Preface: Fungal Infections Luis Ostrosky-Zeichner and Jack D. Sobel xiii The Global Burden of Fungal Diseases 1 Snigdha Vallabhaneni, Rajal K. Mody, Tiffany Walker, and Tom Chiller Fungal
More informationNew antifungal agents
New antifungal agents Dr Atul Patel, MD, FIDSA Chief Consultant and Director Infectious Diseases Clinic Vedanta Institute of Medical Sciences Ahmedabad, India Presented at MMTN Malaysia Conference 5 6
More informationUse of Antifungals in the Year 2008
Use of Antifungals in the Year 2008 Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine Diagnosis
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationNewer Combination Therapies
Newer Combination Therapies William J. Steinbach, MD Associate Professor of Pediatrics, Molecular Genetics & Microbiology Pediatric Infectious Diseases Duke University Medical Center Combination Therapy
More informationSeries. Fungal infections 5 The global problem of antifungal resistance: prevalence, mechanisms, and management
Fungal infections 5 The global problem of antifungal resistance: prevalence, mechanisms, and management David S Perlin, Riina Rautemaa-Richardson, Ana Alastruey-Izquierdo All serious fungal infections
More informationWelcome to the 8 th Advances Against Aspergillosis international conference
Welcome to the 8 th Advances Against Aspergillosis international conference Introduction and summary of global disease burden David W. Denning National Aspergillosis Centre Wythenshawe Hospital The University
More informationHyaline Molds. Aspergillus clavatus. Aspergillus flavus. Aspergillus fumigatus. Aspergillus glaucus. Aspergillus nidulans. Aspergillus niger Complex
Hyaline Molds Aspergillus clavatus Aspergillus flavus Aspergillus fumigatus Aspergillus glaucus Aspergillus nidulans Aspergillus niger Complex Aspergillus terreus Complex Aspergillus ustus Aspergillus
More informationThe incidence of invasive fungal infections
AN EPIDEMIOLOGIC UPDATE ON INVASIVE FUNGAL INFECTIONS * Michael A. Pfaller, MD ABSTRACT *Based on a presentation given by Dr Pfaller at a symposium held in conjunction with the 43rd Interscience Conference
More informationHistopathology Description:
2013-2-1 CANINE HEART Ahmed M. Abubakar BOVINE PATHOLOGY CONTRIBUTING INSTITUTION : The Royal Veterinary college, Dept. of Pathology and Biology Signalment: 11-month-old male Border Collie dog (Canis familiaris)
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationPrimary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts
Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts Dorothy McCoy, Pharm.D., Daryl D. DePestel, Pharm.D., and Peggy L. Carver, Pharm.D. In
More informationAzole-resistant Aspergillus fumigatus isolates carrying TR 34 /L98H mutations in Taiwan
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Azole-resistant Aspergillus fumigatus isolates carrying TR 34 /L98H mutations in Taiwan Chi-Jung Wu, 1,2 Hsuan-Chen Wang, 1
More informationTreatment Guidelines for Invasive Aspergillosis
Treatment Guidelines for Invasive Aspergillosis Thomas F. Patterson, MD Professor of Medicine Director, San Antonio Center for Medical Mycology The University of Texas Health Science Center at San Antonio
More informationESCMID Online Lecture Library. by author
The antibacterial experience: indications for clinical use of antimicrobial combinations To prevent the emergence of resistant organisms (tuberculosis) To treat polymicrobial infections (abdominal complicated
More informationDecision criteria for MALDI-TOF MS-based identification of filamentous fungi using commercial and in-house reference databases
Normand et al. BMC Microbiology (2017) 17:25 DOI 10.1186/s12866-017-0937-2 RESEARCH ARTICLE Decision criteria for MALDI-TOF MS-based identification of filamentous fungi using commercial and in-house reference
More informationInvasive Aspergillosis in Steroid-Treated Patients
Invasive Aspergillosis in Steroid-Treated Patients Dimitrios P. Kontoyiannis, MD, ScD Professor of Medicine Department of Infectious Diseases Infection Control and Employee Health PMN damaging Aspergillus
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationSolid organ transplant patients
M.6 Meet-the-expert sessions Solid organ transplant patients Martin Iversen, Denmark José M. Aguado, Spain Copenhagen, Sunday 13 October 2013 Conflict of interest disclosure In the past 5 years, J.M.A.
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationNijmegen Institute for Infection, Inflammation and Immunity (N4i) 2, Nijmegen, the. and Hematology 4, University Medical Center
JCM Accepts, published online ahead of print on January 0 J. Clin. Microbiol. doi:./jcm.01-0 Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationAntifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside
REVIEW 10.1111/1469-0691.12495 Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside M. Cuenca-Estrella National Center for Microbiology, Instituto de Salud Carlos III, Madrid,
More informationHCDCP. Contents: Highlights. Fungal infections
Hellenic Center for Disease Control and Prevention Agrafon 3-5, Maroussi, 15123, Tel: +30 210 5212000, info@keelpno.gr, http://www.keelpno.gr February 2013 Vol. 24/ Year 2nd ISSN 1792-9016 Contents: Main
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More information